

## Special Issue

# Advances in Stereotactic Radiotherapy of Brain Metastases

### Message from the Guest Editors

The aim of this Special Issue is to initiate a discussion around these novel developments, with the goal of providing clinical answers with a translational perspective. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- What do we know about the importance of immune effects in stereotactic irradiation of brain metastases?
- Single fraction vs. fractionated stereotactic radiotherapy of brain metastases—one fits all?
- Staged radiosurgery of large brain metastases.
- Preoperative stereotactic radiotherapy or postoperative radiotherapy of metastatic bed.
- Can we safely retreat brain metastases after previous stereotactic radiotherapy?
- Do we still need whole-brain irradiation for brain metastases? Pro/con discussion.
- Treatment of brain metastases: single event or long-term management.
- Treatment of oligometastatic brain metastases.

### Guest Editors

Prof. Dr. Florian Wurschmidt

Department of Radiotherapy, Radiology Allianz, Hamburg, Germany

Prof. Dr. Bodo Lippitz

Interdisciplinary Centre for Radiosurgery (ICERA), Radiology Allianz, Hamburg, Germany

### Deadline for manuscript submissions

closed (15 April 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/124803](https://mdpi.com/si/124803)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)